Severity
Moderate
FDA Drug recall · Reported July 10, 2013
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Clinical Specialties Compounding Pharmacy recalled Ophthalmic dilation gel (MAR), Clinical Specialties Compounding Pharmacy, 318 Baston Road… - a moderate-severity action.
Ophthalmic dilation gel (MAR), Clinical Specialties Compounding Pharmacy, 318 Baston Road… was recalled by Clinical Specialties Compounding Pharmacy in July 10, 2013. Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control proces…. Check the official notice for the remedy. Verify recall #D-659-2013 with the FDA Drug before acting.
The recall
Clinical Specialties Compounding Pharmacy issued this moderate-severity FDA Drug recall-Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control proces….
Sourced from official FDA Drug enforcement records. Verify recall #D-659-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-659-2013) was formally reported on July 10, 2013, with the manufacturer initiating the action on March 20, 2013. It is classified under Moderate severity (Class II), with a current status of Terminated. Clinical Specialties Compounding Pharmacy is listed as the recalling firm, operating out of Augusta, GA. Federal records list the affected scope as 360ml total.
The documented reason for this recall is: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes Distribution data in the federal record shows the product reached: FL, GA and SC.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
360ml total
Related Recalls
6
5 from same agency
Ophthalmic dilation gel (MAR), Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-659-2013 |
| Date reported | July 10, 2013 |
| Date initiated | March 20, 2013 |
| Recalling firm | Clinical Specialties Compounding Pharmacy |
| Firm location | Augusta, GA |
| Affected scope | 360ml total |
| Distribution | FL, GA and SC. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 10, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.